Abstract
Unsafe induced abortion is the leading cause of death in women aged 15 to 39 in Latin America and a major cause of maternal mortality throughout the developing world. A medical alternative to early surgical abortion has been developed which could contribute to a reduction in mortality, but which is so far available only in France (1988) and Britain (1991). The method is described, with advantages and disadvantages for use in developing countries. The reason for the pharmaceutical company's reluctance to apply for product licences in other countries is not primarily legal, three-quarters of the women of the world living in countries where abortion is allowed. Nor is it medical, the method having been tested in clinical trials in 20 countries and used by 70 000 women in France. The unusual problem is religious. The company which owns the worldwide patent faces threats from anti-abortion groups, particularly in the US, to their other more profitable products. US government policy is to withdraw funds from overseas abortion aid even in countries where abortion is legal, denying women in developing countries the choice available to women in the US. The role of WHO is crucial in providing access to medical abortion to women in the developing world.